E7389-LF

Phase 1Small molecule

Eisai

E7389-LF is one of 40 small molecule programs targeting Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorActive, not recruiting

Solid TumorPhase 1

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Fludara

Sanofi

Preclinical

2 2

DATROWAY

Daiichi Sankyo

Preclinical

1 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

3 4

Navmi

SSummit Therapeutics

Preclinical

1 5

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

1 7

Tulmimetostat

Novartis

Preclinical

1 8

Carboplatin AUC-5

Merck & Co.

Preclinical

1 9

MHB036C

MMinghui Pharmaceutical (Hangzhou) Ltd

Preclinical

1 10

IN10018

IInxMed (Shanghai) Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Solid Neoplasms

NCT04078295

Phase 1Active, not recruiting

Solid Tumor

NCT03207672

Clinical

Trials by Indication[1]

Solid Neoplasms1 trial

An Open-Label Phase 1b/2 Study of E7389 Liposomal Formulation Plus Nivolumab in Subjects With Solid Tumor

Active, not recruiting· Eisai logo

Eisai·Preclinical·NCT04078295·125 enrolled

Solid Tumor1 trial

An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor

Active, not recruiting· Eisai logo

Eisai·Phase 1·NCT03207672·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for E7389-LF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — E7389-LF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for E7389-LF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eisai

E7389-LF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Solid Neoplasms1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News